key: cord-0863330-b423six3
authors: Sharov, Konstantin S.
title: Adaptation of Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses – A reply to Fear versus Data: Short Communication to International Journal of Antimicrobial Agents
date: 2020-07-10
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106093
sha: cc86b8d0f10299f1e840bb65e10e3dde0feefd14
doc_id: 863330
cord_uid: b423six3

In the current research, we report results of our studying SARS-CoV-2 spread in Russia and adaptation of Russian population to it in March-June 2020. Two groups of people have been investigated: 1) 12,082 persons already proven positive for SARS-CoV-2 (clinical information is studied); 2) 7,864+4,458 persons with respiratory suspicions (PCR tests and clinical information). In the latter, SARS-CoV-2 positive persons comprised 5.37% in March and 11.42% in June 2020. A number of viral co-infections was observed for SARS-CoV-2. Rhinoviruses accounted for the largest co-infection part (7.91% of samples tested positive for SARS-CoV-2); respiratory syncytial virus 7.03%; adenoviruses 4.84%; metapneumoviruses 3.29%; parainfluenza viruses 2.42%; enterovirus D68 1.10% and some other viruses (entero-, echo-, parecho-) less than 1%. In the group of 12,537 humans, SARS-CoV-2 case fatality rate was determined to be 0.6% on average (in contrast with official Russian governmental statistics that reports 1.5% mortality). It is within range of mortality caused by other common seasonal respiratory viruses (0.01-2.21% in Russia in 2012-2020 range). Most of deaths were of people with other comorbidities, also similar with different respiratory viruses. Proportion of SARS-CoV-2 asymptomatic carriers was 56.68% in March and 70.67% in June 2020. Obviously, this new pathogen presents a substantial risk to human population, as it was not contained at the very beginning of its outbreak in Wuhan and spread to the whole world. However, measures of its surveillance, prevention and treatment must be strictly evidence-based and not dictated by fear.

In their paper "SARS-CoV-2: fear versus data" of Roussel et al. [1] , the authors noted that "systematic studies of other coronaviruses (but not yet for SARS-CoV-2) have found that the percentage of asymptomatic carriers is equal to or even higher than the percentage of symptomatic patients. The same data for SARS-CoV-2 may soon be available, which will further reduce the relative risk associated with this specific pathology." As corona situation evolves, it becomes clear that, just like for other coronaviruses and many other acute respiratory infection (ARI) viruses, SARS-CoV-2 asymptomatic carriers constitute a considerable proportion of population, especially in children and adolescents groups [2] [3] [4] [5] [6] [7] . The presence of such substantial proportion of asymptomatic carriers may evidence not only an increased risk of hidden contagiousness [8] , but, more importantly, not so great hazard of SARS-CoV-2 to population, as it was thought by world community at the beginning of the outbreak [9] [10] . The real risk of SARS-CoV-2 to population, as Jean-Marc Rolain and Po-Ren Hsueh with their research teams specified, may be assessed by studying 1) the proportion of asymptomatic patients; 2) COVID-19 clinical manifestation for different groups of population; 3) mortality;

and comparing these indicators with other ARI viruses that appear in population mainly on a seasonal basis [11] . Now, when the first fears connected with a new pathogen have subsided, scientific groups and medical care sector must evaluate real level of threat associated with COVID-19, not the imaginary horrors boosted by media [1, [12] [13] [14] , since "fear could have a larger impact than the virus itself" [1] . In Russia, within official programme of screening population for SARS-CoV-2, 584,680 respiratory samples were found to be positive with around 17 million tests made (11.64% of Russian population already tested) at the national level, as of 20 June 2020. Our study may further elaborate the conclusions of Jean-Marc Rolain, Didier Raoult and the research team from Assistance Publique-Hôpitaux de Marseille and can be of interest for different European countries.

In the current Short Communication, we are providing an up-to-date (as of 20 June 2020) information about the number of asymptomatic patients, comorbidities, mortality rate associated with SARS-CoV-2, patients with different coronaviruses and ARI viruses, shifts in ARI panel composition from March to June, age breakdown of COVID-19 clinical course, and viral coinfections in COVID-19 patients/carriers in Russia.

We investigated samplings and clinical information on people with respiratory suspicions from twelve Russian hospitals transformed to COVID-19 infirmaries, twenty-two outpatients' clinics and ambulance centres, and eight non-commercial test labs and medical centres (Moscow, home and in hospitals, were investigated. Only clinical information was studied for this set. Age, gender, results of clinical blood/urine tests, symptomatic picture and outcome were known.

The work has been carried out in two time intervals: 1) since 2 March to 30 April 2020; and 2) 

OriginLab Origin 8.1 was used for statistical calculations and visualisation.

Reporting of the study conforms to broad EQUATOR [15] and STROBE-NI cohort studies [16] guidelines. All clinical information studied in the current work, was completely anonymised. In hospitals and clinics involved in treating the patients, a written informed consent has been taken from every patient concerned that he/she gives a clear permission to use their data for scientific research and publications. All written informed consents duly signed are kept in the hospitals, clinics, ambulance and medical centres. The Ethical Committee of Koltzov Institute of Developmental Biology of Russian Academy of Sciences regarded the current study ethically appropriate and exempt from human subjects review, as no clinical trials were performed, the authors were not personally involved in collecting the clinical data in medical institutions and hence do not possess any information that might identify the patients.

As the research teams from Assistance Publique-Hôpitaux de Marseille mentioned, there are four coronaviruses in circulation with fatality rates comparable to SARS-CoV-2 [1, 17] . As of 19

February 2020, these teams tested 4,084+5,080 samples and revealed the presence of two alphaand two beta-common seasonal human coronaviruses in the samples, and no samples with SARS-CoV-2 were present [17] . The change of different viruses proportion in ARI group studied, with transition from time period 1 to time period 2, is provided in Figure 1 , panel E. This factor was calculated as follows:

. We see that the rise in SARS-CoV-2 part in the entire ARI viral panel is observable, but not dramatic. OC43 proportion increased much more (probably, due to a local surge in Far East Russian regions). SARS-CoV-2 increase is comparable with increase of enteroviruses, echoand parechoviruses in ARI viral panel, and these viruses are far from causing any epidemic in Russia nowadays. This finding may indicate that SARS-CoV-2 contagiousness is not very high (its basic reproduction number is not very large for any environment); therefore, the virus spread is limited. Along with the observation that the part of SARS-CoV-2 asymptomatic carriers augmented from time interval 1 to time interval 2, viz. from 56.68% to 70.67% (Figure 1 , panels B and D), it may be an evidence that population is already gradually adapting to the new pathogen.

We detected the ability of SARS-CoV-2 to make viral co-infections with different ARI viruses.

Around one quarter of all 455 SARS-CoV-2 positive samples from sampling set 1 contained another viral RNAs or DNAs (Figure 1, panel F) . Rhinoviruses accounted for the largest coinfection part (7.91% of samples tested positive for SARS-CoV-2); respiratory syncytial virus 7.03%; adenoviruses 4.84%; metapneumoviruses 3.29%; parainfluenza viruses 2.42%; enterovirus D68 1.10% and other viruses (entero-, echo-, parecho-) less than 1%. Respiratory viral co-infections are not something extraordinary or novel. The ability of many human respiratory viruses to engage in co-infections is known [18] . For SARS-CoV-2, some cases of viral co-infections have been already recently reported [19, 20] . In our research, we found that viral co-infection cases with SARS-CoV-2 were predominantly related to minor patients/carriers (on or below 17 years old) and adult patients up to 45 years old, with decay after this age. That may indicate a possible connection with the most active period of life. Anyway, cases of respiratory viral co-infections with SARS-CoV-2 were not proven to be related to immune system dysfunction.

It is interesting that no co-infections of SARS-CoV-2 with another coronaviruses or influenza viruses were detected. A possible explanation may consist in their similar stereometric configuration (size, conformation of envelope proteins) and/or molecular mechanisms of attachment to cellular surface in a human organism, that may result in their competitive exclusion. The presence of ACE2 receptor may also play a role here [13] .

Of 455 SARS-CoV-2 positive samples, no triple viral co-infections were revealed.

The mortality registered for sampling sets 1 and 2 combined, is presented in Figure 2 , panel A, separately for time intervals 1 and 2. The comparison with statistics collected for Russia in 2012-2020 period, demonstrates that SARS-CoV-2 cannot be regarded exceptionally "deadly," as, say, Ebola haemorrhagic fever or H5N1 highly pathogenic "bird" flu, i.e. its case fatality rate is not high, despite what was initially thought of it in January-February 2020. As we can see in Figure 2 , panel A, many ARI viruses bring on similar or greater fatality rates. Most of them have case fatality rates very close to 1 per cent or between 1 and 2 per cent. SARS-CoV-2 main danger remains to be associated with its free spread around the world in the situation of truly globalised humanity without mental, religious, racial, ethnic, national, cultural or any other borders, the world with enormous tourist and supply chain torrents [21] . It is this persistent worldwide spread of the virus that causes many lethal cases, not its putative "deadliness."

The current official COVID-19 case fatality rate for Russia is 1.4-1.5% [22] . Fatality age breakdown (official data for the end of April 2020): 0.6% (18-29 years); 14.2% (30-49); 19.6% (50-64); 65.6% (65+) [22] . In sampling sets 1 and 2 combined, median case fatality rate was 0.6%. In any case, the careful analysis of clinical information shows that the overwhelming majority of deaths were cases with comorbidities. Of 477 death cases (sampling set 1) available for our analysis, 442 cases (92.6%) were represented by patients with at least one comorbidity.

The most common comorbidities: metabolism disorders, including diabetes, obesity, gout and hormonal impairments etc. (84%); cardiovascular diseases, including hypertension, ischaemic heart disease, cardiac decompensation, stenocardia, coronary artery disease etc. (82%); bad habits following, including chronic alcoholism, constant smoking and narcotic addiction (21%); internal organ diseases, including functional impairments, such as COPD, asthma, kidney and liver diseases (18%); neurological diseases (15%), oncology (10%); immune system disorders (3%).

On average, 54.5% of COVID-19 patients from sampling set 2, and treated both at home and in hospitals, exhibited no symptoms (time interval 1). 28.6% showed mild symptoms (slight cough, mild pyrexia up to 37.5°C, fatigue, mild upper respiratory tract disease, moderate myalgia, pharyngitis, stuffiness in nose, catarrhal inflammation). 11.0% demonstrated more serious and pronounced symptoms (bronchitis, obliterative bronchiolitis, wheezing, shortness of breath, rapid breathing with cracklings, moderate to strong dry/humid cough, pyrexia up to 38.3°C). But only 5.9% of patients exhibited severe symptoms (viral or bacterial pneumonia of different severity, pyrexia up to 40.1°C with median 38.7°C). Critical patients with acute respiratory distress syndrome and respiratory failure that required ICU use, made up no more than 1.4% of all persons in the set. The number of severe patients was thrice as less in comparison with WHO official predictions. The number of hospital critical patients that required oxygenating ICU treatment, was almost ten times less than predicted by WHO.

Age breakdown of symptomatic clinical course is given in Figure 2, 

In Russia, in January-June 2020, the number of deaths of pneumonia can be estimated as some 16 ,000 people (Rosstat data). Current number of deaths with COVID-19 diagnosed is twice less.

It is considerable, but proper steps in surveillance, prevention, diagnosis and treatment may effectively curb it. In January-June 2019, there were 15,206 fatalities of pneumonia, and in 2012-2016 approximately 16,000-28,000 humans. Therefore, in Russia the current risk of contagiousness and fatality associated with SARS-CoV-2 (as of 21 June 2020) is statistically comparable with the risk from other human coronaviruses and many other ARI viral pathogens that already became seasonal, and less than that of pneumonia of different aetiology. It does not mean, however, that we may relax, as this emerging pathogen turned out to be less dangerous than we deemed several months ago. A search for new therapeutics must continue along with development of vaccines. None the less, panicking, trembling, or regarding SARS-CoV-2 a once-in-an-age threat and "plague of the twenty-first century" is not productive and sometimes even counterproductive. The measures for containment COVID-19 must be determined by research, statistics and thorough calculations, not by apprehension or fear. 

SARS-CoV-2: Fear versus data

Are children less susceptible to COVID-19?

Treatment Options for COVID-19: The Reality and Challenges

CT features of novel coronavirus pneumonia (COVID-19) in children

SARS-CoV-2 (COVID-19): What do we know about children? A systematic review

Low Transmission Risk of 9 Asymptomatic Carriers Tested Positive for both SARS-CoV-2 Nucleic Acid and Serum IgG

The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak

A study on infectivity of asymptomatic SARS-CoV-2 carriers

De-Creation of Creation, or A New Level of Culture in the Development of homo

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Adaptation to SARS-CoV-2 under stress: Role of distorted information

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

COVID-19 Therapeutic and Prevention

A catalogue of reporting guidelines for health research

Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research

Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2

Exploring Lessons Learned from a Century of Outbreaks: Readiness for 2030

Co-infection with SARS-CoV-2 and Human Metapneumovirus

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Horror Zivilisationis, or the Horror of Subjectivity

Official website of the Russian Official Headquarters on Control and Monitoring of Coronavirus Situation

We would like to thank Wolfgang Sassin (International Institute for Applied System Analysis